// App-Quantinova.ai

5517 : Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

Researchers

Presenter

  • Amit M. Oza

Principal Investigators

  • Alexander A. Fedenko

  • Mikhail Dvorkin

  • Andreia Cristina de Melo

  • Yaroslav V. Shparyk

  • Irina Rakhmatullina

  • Igor Bondarenko

  • Nicoletta Colombo

  • Valentyn Svintsitskiy

  • David Cibula

  • Rbert Pka

  • Ana Oaknin

  • Tamar Safra

  • Beata Mackowiak-Matejczyk

  • Ling Ma

  • Karen Retta McLachlan

  • Sandra Goble

  • Rebecca Sophie Kristeleit

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • St. Petersburg City Oncology Dispensary, Saint-Petersburg, Russian Federation

  • N. N. Blokhin Russian Cancer Research Center, Moscow, Russia

  • Regional Clinical Oncology Dispensary, Omsk, Russian Federation

  • Instituto Nacional de Câncer - Hospital do Câncer II, Rio De Janeiro, Brazil

  • Lviv Regional Oncology Center, Lviv, Ukraine

  • Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan, Ufa, Russian Federation

  • Dnipropetrovsk Medical Academy, Dnipropetrovsk, Ukraine

  • University of Milano-Bicocca and European Institute of Oncology, Milano, Italy

  • National Cancer Institute of the Ministry of Health of Ukraine

  • Kiev, Ukraine

  • First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, Clinical Center, University of Debrecen, Debrecen, Hungary

  • Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus,Barcelona,Spanien

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Bialostockie Centrum Onkologii im.M.Sklodowskiej-Curie, Biaystok, Poland

  • Rocky Mountain Cancer Centers, Lakewood, CO, Clovis Oncology, Inc., Boulder, CO, Guy's and St Thomas’ NHS Foundation Trust, Great Maze Pond, London, United Kingdom

Locations

  • Canada

  • Russia

  • Brazil

  • Ukraine

  • Italy

  • Hungary

  • Spain

  • Israel

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Ovarian cancer

Biomarkers

  • BRCA mutation

Drug/Treatment

  • Carboplatin

  • Paclitaxel

  • Rucaparib

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

Phase

  • III

Study Id's

  • NCT02855944

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved